Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Total Current Liabilities (2023 - 2025)

Beta Bionics (BBNX) has disclosed Total Current Liabilities for 3 consecutive years, with $30.9 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 46.23% to $30.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.9 million through Dec 2025, up 46.23% year-over-year, with the annual reading at $30.9 million for FY2025, 46.23% up from the prior year.
  • Total Current Liabilities hit $30.9 million in Q4 2025 for Beta Bionics, up from $25.4 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $30.9 million in Q4 2025 to a low of $10.6 million in Q4 2023.
  • Historically, Total Current Liabilities has averaged $20.7 million across 3 years, with a median of $20.3 million in 2024.
  • Biggest five-year swings in Total Current Liabilities: surged 99.42% in 2024 and later skyrocketed 46.23% in 2025.
  • Year by year, Total Current Liabilities stood at $10.6 million in 2023, then soared by 99.42% to $21.1 million in 2024, then surged by 46.23% to $30.9 million in 2025.
  • Business Quant data shows Total Current Liabilities for BBNX at $30.9 million in Q4 2025, $25.4 million in Q3 2025, and $19.5 million in Q2 2025.